| 1 Slower progression or improvement in GFR (mL per min per 1·73 m²) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.1 at 18 to 24 months |
1 |
|
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 2 Improvement in ability to concentrate urine (mOsm/kg) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 2.1 at 18 to 24 months |
1 |
|
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 3 SAEs assessed with acute chest syndrome |
1 |
|
Risk Ratio (M‐H, Random, 99% CI) |
Totals not selected |
| 4 SAEs assessed with painful crisis |
1 |
|
Risk Ratio (M‐H, Random, 99% CI) |
Totals not selected |
| 5 SAEs assessed with hospitalisations |
1 |
|
Risk Ratio (M‐H, Random, 99% CI) |
Totals not selected |
| 6 SAEs assessed with stroke |
1 |
|
Peto Odds Ratio (Peto, Fixed, 99% CI) |
Totals not selected |
| 7 AEs assessed with neutropenia |
1 |
|
Risk Ratio (M‐H, Random, 99% CI) |
Totals not selected |
| 8 AEs assessed with thrombocytopenia |
1 |
|
Risk Ratio (M‐H, Random, 99% CI) |
Totals not selected |
| 9 Number of participants transfused |
1 |
|
Risk Ratio (IV, Random, 95% CI) |
Totals not selected |
